Summary & Overview
CPT 64633: Neurolytic Destruction of Cervical/Thoracic Facet Joint Nerves
CPT code 64633 is a key billing code for pain management specialists performing neurolytic destruction of paravertebral facet joint nerves in the cervical or thoracic spine. This procedure, guided by imaging such as fluoroscopy or CT, is widely used to treat chronic pain conditions related to facet joint dysfunction. The code is relevant for physicians in pain medicine, physical medicine and rehabilitation, and internal medicine who provide interventional spine procedures in ambulatory surgical centers or office settings with imaging capabilities.
Major national payers covering this code include Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare. The publication provides an overview of payer coverage, clinical indications, and related billing codes, offering readers insight into current policy updates and reimbursement benchmarks. It also highlights common modifiers used in billing and the associated ICD-10 diagnoses for spondylosis and other dorsopathies. Readers will gain a comprehensive understanding of the clinical context, payer landscape, and coding nuances for CPT 64633, supporting informed decision-making in pain management billing and compliance.
CPT Code Overview
CPT code 64633 describes the destruction of paravertebral facet joint nerve(s) in the cervical or thoracic regions using a neurolytic agent, such as chemical, thermal, electrical, or radiofrequency methods. This procedure is performed with imaging guidance, typically fluoroscopy or CT, to ensure precision. It is commonly utilized in pain management and interventional spine procedures to address chronic pain associated with facet joint pathology. The typical site of service includes ambulatory surgical centers or office settings equipped with imaging capabilities, such as POS 11 or ASC.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult presenting with chronic neck or upper back pain attributed to facet joint pathology, such as spondylosis or other specified dorsopathies in the cervical or thoracic regions. The patient has not responded adequately to conservative treatments like physical therapy or medications. After clinical evaluation and diagnostic imaging, the provider determines that destruction of the paravertebral facet joint nerve(s) using a neurolytic agent is indicated to manage pain. The procedure is performed in an ambulatory surgical center or office setting equipped with fluoroscopy or CT imaging guidance. The workflow includes pre-procedure assessment, imaging-guided localization of the target nerve(s), application of the neurolytic agent, and post-procedure monitoring.
Coding Specifications
| Modifier Code | Description | When to Use |
|---|---|---|
50 | Bilateral procedure | When the procedure is performed on both sides of the spine (left and right facet joints). |
LT | Left side | When the procedure is performed only on the left side. |
RT | Right side | When the procedure is performed only on the right side. |
KX | Requirements specified in the medical policy have been met | When documentation supports that payer-specific medical policy criteria are satisfied. |
Associated Provider Taxonomies:
208VP0000X- Pain Medicine Physician207LP2900X- Physical Medicine & Rehabilitation Physician207R00000X- Internal Medicine Physician
These specialties are typically involved in pain management and interventional spine procedures.
Related Diagnoses
-
M47.812- Spondylosis without myelopathy or radiculopathy, cervical region- Indicates degenerative changes in the cervical spine, relevant for facet joint pain treated by this procedure.
-
M47.813- Spondylosis without myelopathy or radiculopathy, cervicothoracic region- Refers to spondylosis at the junction of cervical and thoracic spine, a potential source of facet pain.
-
M47.814- Spondylosis without myelopathy or radiculopathy, thoracic region- Thoracic spondylosis can cause facet joint pain managed by neurolytic destruction.
-
M47.815- Spondylosis without myelopathy or radiculopathy, thoracolumbar region- While primarily lumbar, may be relevant if pain extends to thoracic region.
-
M47.816- Spondylosis without myelopathy or radiculopathy, lumbar region- Not directly related to cervical/thoracic procedures, but included for completeness.
-
M47.817- Spondylosis without myelopathy or radiculopathy, lumbosacral region- Similar to above, included for comprehensive coding.
-
M47.892- Other spondylosis, cervical region- Covers other forms of cervical spondylosis relevant to facet pain.
-
M47.893- Other spondylosis, cervicothoracic region- Includes other spondylosis types at the cervicothoracic junction.
-
M47.894- Other spondylosis, thoracic region- Other thoracic spondylosis types, relevant for thoracic facet procedures.
-
M47.895- Other spondylosis, thoracolumbar region- Included for completeness.
-
M47.896- Other spondylosis, lumbar region- Not directly related to cervical/thoracic procedures.
-
M47.897- Other spondylosis, lumbosacral region- Included for comprehensive coding.
-
M48.12- Ankylosing hyperostosis [Forestier], cervical region- Forestier's disease in the cervical spine can cause facet pain.
-
M48.13- Ankylosing hyperostosis [Forestier], cervicothoracic region- Forestier's disease at the cervicothoracic junction.
-
M48.14- Ankylosing hyperostosis [Forestier], thoracic region- Forestier's disease in the thoracic spine.
-
M48.15- Ankylosing hyperostosis [Forestier], thoracolumbar region- Included for completeness.
-
M48.16- Ankylosing hyperostosis [Forestier], lumbar region- Not directly related to cervical/thoracic procedures.
-
M48.17- Ankylosing hyperostosis [Forestier], lumbosacral region- Included for comprehensive coding.
-
M53.82- Other specified dorsopathies, cervical region- Other cervical spine disorders relevant to facet pain.
-
M53.83- Other specified dorsopathies, cervicothoracic region- Other disorders at the cervicothoracic junction.
-
M53.84- Other specified dorsopathies, thoracic region- Other thoracic spine disorders relevant to facet pain.
-
M53.85- Other specified dorsopathies, thoracolumbar region- Included for completeness.
-
M53.86- Other specified dorsopathies, lumbar region- Not directly related to cervical/thoracic procedures.
-
M53.87- Other specified dorsopathies, lumbosacral region- Included for comprehensive coding.
Related CPT Codes
-
64634- Destruction by neurolytic agent (eg, chemical, thermal, electrical or radiofrequency), paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT), each additional facet joint, cervical or thoracic- Used in conjunction with
64633when more than one cervical or thoracic facet joint is treated during the same session.
- Used in conjunction with
-
64635- Destruction by neurolytic agent (eg, chemical, thermal, electrical or radiofrequency), paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT), single facet joint, lumbar or sacral- Used for similar procedures in the lumbar or sacral regions, as an alternative to
64633when the anatomical site differs.
- Used for similar procedures in the lumbar or sacral regions, as an alternative to
-
64636- Destruction by neurolytic agent (eg, chemical, thermal, electrical or radiofrequency), paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT), each additional facet joint, lumbar or sacral- Used with
64635when treating more than one lumbar or sacral facet joint in the same session.
- Used with
Codes 64634 and 64636 are add-on codes, commonly used together with their respective primary codes (64633 or 64635) when multiple joints are treated.
National Reimbursement Benchmarks
For CPT code 64633, the national mean rate for Medicare is $476.92, closely aligned with the BUCA (average commercial) mean rate of $477.25. Commercial payers such as UnitedHealth Group and Cigna show higher mean rates, with UnitedHealth Group at $649.65 and Cigna at $547.87, while Aetna and Blue Cross Blue Shield are lower at $404.26 and $452.05, respectively.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Medicare exhibits the tightest range at $54.00, indicating relatively consistent rates nationally. In contrast, UnitedHealth Group has the widest range at $330.94, reflecting substantial variability in commercial reimbursement. Cigna and Blue Cross Blue Shield also show broad ranges, while Aetna and BUCA are moderately dispersed.
The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.